3MASLD = metabolic dysfunction-associated steatotic liver disease; HCC = hepatocellular carcinoma; ELF test = enhanced liver fibrosis; FIB-4 index = fibrosis 4
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. In the U.S., the ELF Test is not for use in the diagnosis of NASH, for the staging of fibrosis, or for assessing progression to hepatocellular carcinoma.